Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Fruquintinib in Combination With Everolimus as Second Line Therapy of ccRCC Patients Progressed Post Immunotherapy and Tyrosine Kinase Inhibitors Therapy: a Prospective, Single Arm, Phase II Clinical Trial

NCT06317298 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT06317298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06317298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Fruquintinib in Combination With Everolimus as Second Line Therapy of ccRCC Patients Progressed Post Immunotherapy and Tyrosine Kinase Inhibitors Therapy: a Prospective, Single Arm, Phase II Clinical Trial
Lead sponsor
Peking University First Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
February 21, 2024
Completion date
December 1, 2025
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma, clear cell, somatic